Antibody tests for the novel coronavirus, SARS-CoV2, have been developed both as rapid diagnostic assays and for high-throughput formal
serology platforms. Although these tests may be a useful adjunct to a diagnostic strategy, they have a number of limitations. Because of the
antibody and viral dynamics of the coronavirus, their sensitivity can be variable, especially at early time points after symptom onset. Additional
data are required on the performance of the tests in the South African population, especially with regard to development and persistence of
antibody responses and whether antibodies are protective against reinfection. These tests may, however, be useful in guiding the public health
response, providing data for research (including seroprevalence surveys and vaccine initiatives) and development of therapeutic strategies.